The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000716369p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
25/05/2026
Date registered
Help: Date registered
16/06/2026
Date last updated
Help: Date last updated
16/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The effect of Intranasal insulin compared to usual care for the prevention of delirium in critically ill patients by day 14 or hospital discharge.
Scientific title
Intranasal insulin vs usual care for the prevention of delirium in critically ill patients aged 65 years and over at day 14 or hospital discharge; A multicentre randomised controlled trial
Additional trial identifiers [1] 317381 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Delirium 342041 0
Critically ill patients 342043 0
Condition category
Condition code
Neurological 338131 338131 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
30 IU of short acting insulin (insulin aspart) given intranasally twice a day (morning 8 am and Evening 6 pm) by bedside nurse or study staff for a maximum of 5 days while monitored in an Intensive Care Unit.
There will be an accountability log for administration verified and signed by administering staff
Intervention code [1] 334173 0
Treatment: Drugs
Description of the comparator or control
The comparator is usual care. All participants in the control group will receive the usual ICU treatment for the primary admission diagnosis as per treating team. No specific therapies will be mandated and the Usual clinician-dependent approach to the management of delirium risk.
Control group
Active

Outcomes
Primary outcome [1] 345520 0
The proportion of patients remaining delirium free, assessed twice daily using CAM-ICU or 4-AT, by day 14 or by hospital discharge whichever comes first.
Timepoint [1] 345520 0
day 14 post first dose or by hospital discharge whichever comes first.
Secondary outcome [1] 462013 0
time to first delirium episode
Timepoint [1] 462013 0
day 14 post first dose or by hospital discharge whichever comes first
Secondary outcome [2] 462014 0
duration of delirium
Timepoint [2] 462014 0
by day 14 post first dose or by hospital discharge whichever comes first
Secondary outcome [3] 462015 0
Days alive and free of coma and delirium will be assessed as a composite outcome
Timepoint [3] 462015 0
At 14 days post first dose
Secondary outcome [4] 462017 0
ICU length of stay
Timepoint [4] 462017 0
Measured at 14 days post first dose
Secondary outcome [5] 462019 0
Quality of life measured by Short (short informant questionnaire on cognitive decline in the elderly (IQCODE)
Timepoint [5] 462019 0
at 3 months post first dose
Secondary outcome [6] 462786 0
Hospital length of stay
Timepoint [6] 462786 0
At hospital discharge

Eligibility
Key inclusion criteria
Patients must have ALL of the following for inclusion:
1. Equal or greater than 65 years old
2. Delirium free
3. Expected to be in ICU = 48 hours
Minimum age
65 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. if their survival expectation is less than 7 days,
2. are allergic to insulin,
3. have structural abnormality that precludes the use of intranasal drug delivery,
4. are unable to participate in delirium assessment using CAM-ICU or 4-AT,
5. have a neurological disease with reduced level of consciousness assessed by Glasgow Coma Scale (GCS) of < 13.
6. Diabetic patients receiving insulin or hypoglycaemic agents
7. have fulminant liver failure,
8. on multiple antipsychotic medications,
9. Admitted with an overdose
10. judged to be unsuitable by treating clinician.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation via study website
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 29538 0
Prince of Wales Private Hospital - Randwick
Recruitment hospital [2] 29539 0
Dandenong Hospital- Monash Health - Dandenong
Recruitment hospital [3] 29540 0
Casey Hospital - Berwick
Recruitment hospital [4] 29541 0
Victorian Heart Hospital - Clayton
Recruitment hospital [5] 29542 0
Monash Medical Centre - Clayton campus - Clayton
Recruitment postcode(s) [1] 45860 0
2031 - Randwick
Recruitment postcode(s) [2] 45861 0
3175 - Dandenong
Recruitment postcode(s) [3] 45862 0
3806 - Berwick
Recruitment postcode(s) [4] 45863 0
3168 - Clayton

Funding & Sponsors
Funding source category [1] 321955 0
Charities/Societies/Foundations
Name [1] 321955 0
Prince of Wales Hospital Foundation
Country [1] 321955 0
Australia
Primary sponsor type
Government body
Name
South Eastern Sydney Local Health District
Address
Country
Australia
Secondary sponsor category [1] 324829 0
None
Name [1] 324829 0
Address [1] 324829 0
Country [1] 324829 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 320492 0
South Eastern Sydney Local Health District HREC
Ethics committee address [1] 320492 0
Ethics committee country [1] 320492 0
Australia
Date submitted for ethics approval [1] 320492 0
19/06/2026
Approval date [1] 320492 0
Ethics approval number [1] 320492 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150646 0
Prof Yahya Shehabi
Address 150646 0
Barker Street - Prince of Wales Hospital - Randwick NSW 2031
Country 150646 0
Australia
Phone 150646 0
+61 0419 296 986
Fax 150646 0
Email 150646 0
Contact person for public queries
Name 150647 0
Lewis Raymond
Address 150647 0
Barker Street - Prince of Wales Hospital - Randwick NSW 2031
Country 150647 0
Australia
Phone 150647 0
+61293829360
Fax 150647 0
Email 150647 0
Contact person for scientific queries
Name 150648 0
Yahya Shehabi
Address 150648 0
Barker Street - Prince of Wales Hospital - Randwick NSW 2031
Country 150648 0
Australia
Phone 150648 0
+61 0419 296 986
Fax 150648 0
Email 150648 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.